MENU Quick Go

  • HOME
  • News
  • PharmAbcine Notice
PharmAbcine Notice
`` Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model`` is now indexed on PubMed.
Date 2018-03-25 Hit 173
Attach Files  

" Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model"  is now indexed on PubMed.


PharmAbcine, a clinical stage immune-oncology company, today announced that " Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model " is now indexed on PubMed.


PONE-D-17-27311R2
Evaluation of drug mechanism and efficacy of a novel anti-angiogenic agent, TTAC-0001, using multi-modality bioimaging in a mouse breast cancer orthotopic model


Link to paper on PubMed: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5784895/#__ffn_sectitle

List